Current Edition

data

Khondrion Presents Phase II KHENERGY Trial Data

Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY study, a Phase II exploratory …

Continue Reading →